Q2 2025 Asker Healthcare Group AB Earnings Call Transcript
Key Points
- Asker Healthcare Group AB (OSTO:ASKER) reported a solid performance with a 12% increase in adjusted EBITDA, despite a 3% negative impact from FX effects.
- The company achieved a 9% increase in net sales, reaching SEK4 billion, with organic growth contributing 7% and acquisitions adding another 8%.
- The EBITA margin improved to 9.5%, moving steadily towards the mid-term target of 10%.
- Asker Healthcare Group AB has a strong acquisition pipeline, with the ability to pick and choose the best companies, having acquired five companies in the first half of the year.
- The company maintains a low leverage ratio of 1.8x, providing financial flexibility for future acquisitions and growth opportunities.
- The company faced headwinds from FX translation effects, which reduced the adjusted EBITA growth from 15% to 12%.
- Region North experienced a decline in EBITA due to irregular project-based sales activities, particularly in defense and preparedness areas.
- Operating cash flow was lower compared to the high levels seen in Q2 2024, partly due to the absence of project-based sales in North.
- The company is experiencing slower-than-expected defense volume orders, impacting sales in Region North.
- There is uncertainty regarding the timing of defense volume orders, which could affect future revenue projections.
Thank you very much, and welcome to the Q2 report from Asker Healthcare Group. This is our second report in the listed environment. For me it's 13th year. So it's more of the same and no drama and aesthetic performance is first of year makes me proud of what we do.
If we have a look at the second quarter isolated. We see a solid performance from the 50+ companies across 17 markets. However, we have a little bit of a headwind from translation effects of FX. So they're actually growing adjusted EBITA with 15%, but with a 3% of FX effect makes it down to 12%. So good solid performance, however, no had a little bit of a drawback from project sales.
We're going to come back to that later on. So they were meeting very strong quarters last year. But underlying businesses are in good shape, so all in all good. Adjusted EBITDA , which is our most important KPI, increased 12% after the 3% effect impact. Good to see that organically we're growing 7%. And the accusations added another eight. Net sales were up 9% to SEK4 billion, also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
